Scientists test new combo in fight against aggressive blood cancers
NCT ID NCT05636514
Summary
This early-stage study aims to find the safest dose of a new two-drug combination for adults with high-risk forms of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), or chronic myelomonocytic leukemia (CMML). All 12 participants will first take an approved oral medication (ASTX727) for one month, then add an experimental drug (defactinib) to see if the combination is tolerable. The main goal is to check for serious side effects and determine the maximum dose patients can handle.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Concord Repatriation and General Hospital
RECRUITINGSydney, New South Wales, 2139, Australia
Contact
-
Nepean Hospital
RECRUITINGSydney, New South Wales, 2747, Australia
Contact
-
Prince of Wales Hospital
RECRUITINGSydney, New South Wales, 2031, Australia
Contact
-
Royal Prince Alfred Hospital
RECRUITINGSydney, New South Wales, 2050, Australia
Contact
-
Westmead Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Contact
Conditions
Explore the condition pages connected to this study.